Local Application of Combined Optical and Magnetic Stimulation (COMS) for Treatment of Chronic Wounds: Safety Evaluation

Piomic Medical

Status

Completed

Conditions

Leg Ulcers Venous

Leg Ulcer Arterial

Leg Ulcer Mixed

Treatments

Device: Pio Medical Device

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT03112395

COMS_01

Details and patient eligibility

About

The demographic shift and the increasing prevalence of chronic wounds represent major challenges for modern health care systems. Classic chronic wounds (venous ulcer, arterial ulcer, mixed ulcer) persist for months or years with a very slow or even no healing progress. Patients suffer from pain and immobility, which dramatically reduces their quality of life. Complications such as infections or tissue necrosis can lead to a bad outcome and amputation of extremities.

The Pio device offers a non-invasive and non-toxic therapeutic approach. The system combines the technologies of pulse modulated magnetic fields and light emission locally applied to the wound area. The investigational medical device represents a promising combinational therapeutic approach to synergistically increase the tissues regenerative potential. By stimulating electrophysiological processes at the site of injury, the cells regain its capacity to efficiently regenerate the injured or diseased tissue. It is expected that the patient benefits from a faster healing process, reduced inflammation as well as an improved overall treatment outcome.

Enrollment

36 patients

Sex

All

Ages

18 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Informed Consent as documented by signature (Appendix Informed Consent Form)
Male and female patients
Age: 18 - 90
Chronic wound (venous ulcer, arterial ulcer, mixed ulcer) since at least 4 weeks
Wound area minimal 1 cm2, maximal 50 cm2
No adaptions for treatment of causal therapy of disease

Exclusion criteria

Women who are pregnant
Known or suspected non-compliance, drug or alcohol abuse,
Participation in another study with investigational drug within the 30 days preceding and during the present study,
Enrolment of the investigator, his/her family members, employees and other dependent persons,
Patients with active devices (e.g. Pacemakers and defibrillators, infusion devices, insulin pumps)
Metallic implants and endoprosthesis at extremities lower than hip
Life threatening condition
Immunosuppressive after foreign organ transplant or chemotherapeutic treatment within 30 days before study begin